Search results
Results from the WOW.Com Content Network
In first-line, for hormone receptor (HR)–positive MBC, when a non-steroidal aromatase inhibitor and CDK 4/6 inhibitor combination is unavailable, use hormonal therapy alone. For life-threatening disease, use single-agent chemotherapy or surgery for local control.
Researchers are working to develop new breast cancer treatment breakthroughs, such as more effective drugs that will specifically target breast cancer cells, minimize side effects and prevent breast cancer cells from coming back.
Many new treatments for metastatic breast cancer are under study and treatment is improving. Most of these new treatments are drug therapies. Findings from clinical trials will determine whether or not these new treatments become a part of the standard of care for metastatic breast cancer.
An experimental immunotherapy that uses a person’s own immune cells could potentially treat metastatic breast cancer unresponsive to other treatments.
2024 Year in Review : Therapeutics, Diagnostics, and Deep Learning Models Metastatic Breast Cancer Metastatic Breast Cancer Itovebi Receives FDA Approval for Advanced/Metastatic Breast Cancer Continued on next slide On October 10, the FDA approved inavolisib (Itovebi, Genentech) with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone ...
New research from Stanford and the Arc Institute could lead to a new and more effective immunotherapy and help clinicians better predict patient response to existing medicines. Songnan Wang (left) and Lingyin Li (right) found that a protein called ENPP1 acts as an on/off switch for breast cancer metastases.
Research presented at the ASCO Annual Meeting 2024 highlighted treatments that may improve outcomes for patients with metastatic breast cancer.
“Our findings show that pre-treatment with the HDAC inhibitor entinostat and the use of dual immune checkpoint inhibitors is a safe and promising strategy for metastatic breast cancer, warranting further clinical evaluation in a phase II study,” says lead author Evanthia Roussos Torres, M.D., Ph.D., an assistant professor at the University of So...
The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease, drugmaker Novartis said...
Enhertu expected to become new standard for treating metastatic breast cancer with low HER2 protein levels. Trastuzumab was developed in the 1990s specifically to treat breast cancer.